Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl Swedberg

Showing results (301-310 of 471) with videos related to

Pageof 48
Sort By:
Journal of Cardiac Failure|July 3, 2007
The safety of amiodarone in patients with heart failureChristian Torp-Pedersen, Marco Metra, Philip Spark, et al.
American Heart Journal|April 23, 2005
Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMETChristian Torp-Pedersen, Philip A Poole-Wilson, Karl Swedberg, et al.
Journal of the American College of Cardiology|December 6, 2008
Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) ProgramPeter A Meredith, Jan Ostergren, Inder Anand, et al.
Journal of the American College of Cardiology|December 3, 2016
Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart FailureMichael R Zile, Brian L Claggett, Margaret F Prescott, et al.
The American Journal of Cardiology|March 3, 2015
Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial)Sadiya S Khan, Umberto Campia, Ovidiu Chioncel, et al.
Journal of the American College of Cardiology|July 16, 2016
Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure HospitalizationAkshay S Desai, Brian L Claggett, Milton Packer, et al.
Journal of the American College of Cardiology|March 6, 2007
Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMETWillem J Remme, Christian Torp-Pedersen, John G F Cleland, et al.
Heart Failure Reviews|September 21, 2011
A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trialMihai Gheorghiade, Peter S Pang, Andrew P Ambrosy, et al.
European Heart Journal|July 26, 2005
Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trialMarco Metra, Christian Torp-Pedersen, Karl Swedberg, et al.
ESC Heart Failure|October 20, 2020
Relationship between duration of heart failure, patient characteristics, outcomes, and effect of therapy in PARADIGM-HFSu E Yeoh, Pooja Dewan, Akshay S Desai, et al.
Pageof 48

Showing results (301-310 of 471) with videos related to

Sort By:
Pageof 48
Journal of Cardiac Failure|July 3, 2007
The safety of amiodarone in patients with heart failureChristian Torp-Pedersen, Marco Metra, Philip Spark, et al.
American Heart Journal|April 23, 2005
Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMETChristian Torp-Pedersen, Philip A Poole-Wilson, Karl Swedberg, et al.
Journal of the American College of Cardiology|December 6, 2008
Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) ProgramPeter A Meredith, Jan Ostergren, Inder Anand, et al.
Journal of the American College of Cardiology|December 3, 2016
Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart FailureMichael R Zile, Brian L Claggett, Margaret F Prescott, et al.
The American Journal of Cardiology|March 3, 2015
Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial)Sadiya S Khan, Umberto Campia, Ovidiu Chioncel, et al.
Journal of the American College of Cardiology|July 16, 2016
Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure HospitalizationAkshay S Desai, Brian L Claggett, Milton Packer, et al.
Journal of the American College of Cardiology|March 6, 2007
Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMETWillem J Remme, Christian Torp-Pedersen, John G F Cleland, et al.
Heart Failure Reviews|September 21, 2011
A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trialMihai Gheorghiade, Peter S Pang, Andrew P Ambrosy, et al.
European Heart Journal|July 26, 2005
Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trialMarco Metra, Christian Torp-Pedersen, Karl Swedberg, et al.
ESC Heart Failure|October 20, 2020
Relationship between duration of heart failure, patient characteristics, outcomes, and effect of therapy in PARADIGM-HFSu E Yeoh, Pooja Dewan, Akshay S Desai, et al.
Pageof 48